Description of the efficacy and safety of three new biologics in the treatment of rheumatoid arthritis

Korean Journal of Internal Medicine

Volumn 25, Issue 1, 2010, Pages 1-17

  Storage, Steven S ^a   Agrawal, Harsh ^a   Furst, Daniel E ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Abatacept; Arthritis; Biological products; Golimumab; Rheumatoid; Tocilizumab

Indexed keywords

ABATACEPT; ANTIRHEUMATIC AGENT; AZATHIOPRINE; BUCILLAMINE; C REACTIVE PROTEIN; CHLOROQUINE; CORTICOSTEROID; CYCLOSPORIN; ETANERCEPT; GOLD; GOLIMUMAB; HEMOGLOBIN; HYDROXYCHLOROQUINE; IMMUNOSUPPRESSIVE AGENT; INFLIXIMAB; LEFLUNOMIDE; METHOTREXATE; MIZORIBINE; NONSTEROID ANTIINFLAMMATORY AGENT; PENICILLAMINE; RECOMBINANT INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; SALAZOSULFAPYRIDINE; TOCILIZUMAB; TUMOR NECROSIS FACTOR; TUMOR NECROSIS FACTOR ALPHA INHIBITOR; TUMOR NECROSIS FACTOR INHIBITOR; VASCULOTROPIN;

ABDOMINAL PAIN; ABORTION; ABSCESS; AUTOIMMUNE DISEASE; BASAL CELL CARCINOMA; BLADDER CANCER; BREAST CANCER; CARDIOVASCULAR DISEASE; CELLULITIS; CENTRAL NERVOUS SYSTEM DISEASE; CEREBROVASCULAR ACCIDENT; CLINICAL TRIAL; COLITIS; COLON CANCER; CONTROLLED CLINICAL TRIAL; COUGHING; DEEP VEIN THROMBOSIS; DIARRHEA; DISEASE ACTIVITY; DISEASE DURATION; DIVERTICULITIS; DIZZINESS; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG ERUPTION; DRUG FATALITY; DRUG INDUCED HEADACHE; DRUG MECHANISM; DRUG SAFETY; DRUG SUBSTITUTION; DRUG WITHDRAWAL; DYSPEPSIA; DYSPNEA; EPIGASTRIC PAIN; EROSION; ERYTHROCYTE SEDIMENTATION RATE; EYE DISEASE; FATIGUE; GASTROINTESTINAL HEMORRHAGE; HEALTH ASSESSMENT QUESTIONNAIRE; HEMATOLOGIC DISEASE; HEMOGLOBIN BLOOD LEVEL; HUMAN; INFECTION; INJECTION SITE REACTION; INSOMNIA; JOINT CAVITY; KIDNEY DISEASE; LIPID BLOOD LEVEL; LIVER FUNCTION; LIVER FUNCTION TEST; LUNG CANCER; LUNG CONGESTION; LUNG DISEASE; LUNG EMBOLISM; LYMPHOMA; MELANOMA; MENTAL DISEASE; MENTAL PERFORMANCE; META ANALYSIS; MONOTHERAPY; MOUTH ULCER; MUSCULOSKELETAL DISEASE; NAUSEA AND VOMITING; NEOPLASM; NEUTROPENIA; OPEN STUDY; PEPTIC ULCER; PHYSICAL PERFORMANCE; PNEUMONIA; POLYP; PROTEIN BLOOD LEVEL; PSORIASIS; RANDOMIZED CONTROLLED TRIAL; REMISSION; REVIEW; RHEUMATOID ARTHRITIS; SCORING SYSTEM; SEPSIS; SIDE EFFECT; SKIN DISEASE; SQUAMOUS CELL CARCINOMA; SYSTEMATIC REVIEW; TREATMENT FAILURE; TREATMENT RESPONSE; TREATMENT WITHDRAWAL; TUBERCULOSIS; UNSPECIFIED SIDE EFFECT; URINARY TRACT INFECTION; VASCULAR DISEASE;

ANTIBODIES, MONOCLONAL; ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; BIOLOGICAL THERAPY; HUMANS; IMMUNOCONJUGATES;

EID: 77949405423     PISSN: 12263303     EISSN: 20056648     Source Type: Journal    
DOI: 10.3904/kjim.2010.25.1.1     Document Type: Review

References (31)

1. Segal B, Rhodus NL, Patel K. Tumor necrosis factor (TNF) inhibitor therapy for rheumatoid arthritis. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 2008;106:778-787.
2. Toussirot E, Wendling D. The use of TNF-alpha blocking agents in rheumatoid arthritis: an update. Expert Opin Pharmacother 2007;8:2089-2107.
3. Mertens M, Singh JA. Anakinra for rheumatoid arthritis: a systematic review. J Rheumatol 2009;36:1118-1125.
4. Dass S, Vital EM, Emery P. Rituximab: novel B-cell depletion therapy for the treatment of rheumatoid arthritis. Expert Opin Pharmacother 2006;7:2559-2570.
5. Kremer JM. Selective costimulation modulators: a novel approach for the treatment of rheumatoid arthritis. J Clin Rheumatol 2005;11(3 Suppl):S55-S62.
6. Tracey D, Klareskog L, Sasso EH, Salfeld JG, Tak PP. Tumor necrosis factor antagonist mechanisms of action: a comprehensive review. Pharmacol Ther 2008;117:244-279.
7. Mima T, Nishimoto N. Clinical value of blocking IL-6 receptor. Curr Opin Rheumatol 2009;21:224-230.
8. Westhovens R, Robles M, Ximenes AC, et al. Clinical efficacy and safety of abatacept in methotrexate-naive patients with early rheumatoid arthritis and poor prognostic factors. Ann Rheum Dis 2009;68:1870-1877.
9. Kremer JM, Westhovens R, Leon M, et al. Treatment of rheumatoid arthritis by selective inhibition of T-cell activation with fusion protein CTLA4Ig. N Engl J Med 2003;349:1907-1915.
10. Kremer JM, Dougados M, Emery P, et al. Treatment of rheumatoid arthritis with the selective costimulation modulator abatacept: twelve-month results of a phase iib, double-blind, randomized, placebo-controlled trial. Arthritis Rheum 2005;52:2263-2271.
11. Kremer JM, Genant HK, Moreland LW, et al. Effects of abatacept in patients with methotrexate-resistant active rheumatoid arthritis: a randomized trial. Ann Intern Med 2006;144:865-876.
12. Genant HK, Peterfy CG, Westhovens R, et al. Abatacept inhibits progression of structural damage in rheumatoid arthritis: results from the long-term extension of the AIM trial. Ann Rheum Dis 2008;67:1084-1089.
13. Kremer JM, Genant HK, Moreland LW, et al. Results of a two-year followup study of patients with rheumatoid arthritis who received a combination of abatacept and methotrexate. Arthritis Rheum 2008;58:953-963.
14. Schiff M, Keiserman M, Codding C, et al. Efficacy and safety of abatacept or infliximab vs placebo in ATTEST: a phase III, multi-centre, randomised, double-blind, placebo-controlled study in patients with rheumatoid arthritis and an inadequate response to methotrexate. Ann Rheum Dis 2008;67:1096-1103.
15. Westhovens R, Kremer JM, Moreland LW, et al. Safety and efficacy of the selective costimulation modulator abatacept in patients with rheumatoid arthritis receiving background methotrexate: a 5-year extended phase IIB study. J Rheumatol 2009;36:736-742.
16. Emery P, Durez P, Dougados M, et al. The impact of T-cell co-stimulation modulation in patients with undifferentiated inflammatory arthritis or very early rheumatoid arthritis: a clinical and imaging study of abatacept. Ann Rheum Dis 2009 Nov 23 [Epub]. DOI: 10.1136/ard.2009.119016.
17. Moreland LW, Alten R, Van den Bosch F, et al. Costimulatory blockade in patients with rheumatoid arthritis: a pilot, dose-finding, double-blind, placebo-controlled clinical trial evaluating CTLA-4Ig and LEA29Y eighty-five days after the first infusion. Arthritis Rheum 2002;46:1470-1479.
18. Genovese MC, Becker JC, Schiff M, et al. Abatacept for rheumatoid arthritis refractory to tumor necrosis factor alpha inhibition. N Engl J Med 2005;353:1114-1123.
19. Schiff M, Pritchard C, Huffstutter JE, et al. The 6-month safety and efficacy of abatacept in patients with rheumatoid arthritis who underwent a washout after anti-tumour necrosis factor therapy or were directly switched to abatacept: the ARRIVE trial. Ann Rheum Dis 2009;68:1708-1714.
20. Westhovens R, Cole JC, Li T, et al. Improved health-related quality of life for rheumatoid arthritis patients treated with abatacept who have inadequate response to anti-TNF therapy in a double-blind, placebo-controlled, multicentre randomized clinical trial. Rheumatology (Oxford) 2006;45:1238-1246.
21. Emery P, Fleischmann RM, Moreland LW, et al. Golimumab, a human anti-tumor necrosis factor alpha monoclonal antibody, injected subcutaneously every four weeks in methotrexate-naive patients with active rheumatoid arthritis: twenty-four-week results of a phase III, multicenter, randomized, double-blind, placebo-controlled study of golimumab before methotrexate as first-line therapy for early-onset rheumatoid arthritis. Arthritis Rheum 2009;60:2272-2283.
22. Kay J, Matteson EL, Dasgupta B, et al. Golimumab in patients with active rheumatoid arthritis despite treatment with methotrexate: a randomized, double-blind, placebo-controlled, dose-ranging study. Arthritis Rheum 2008;58:964-975.
23. Keystone EC, Genovese MC, Klareskog L, et al. Golimumab, a human antibody to tumour necrosis factor {alpha} given by monthly subcutaneous injections, in active rheumatoid arthritis despite methotrexate therapy: the GO-FORWARD Study. Ann Rheum Dis 2009;68:789-796.
24. Smolen JS, Kay J, Doyle MK, et al. Golimumab in patients with active rheumatoid arthritis after treatment with tumour necrosis factor alpha inhibitors (GO-AFTER study): a multicentre, randomised, double-blind, placebo-controlled, phase III trial. Lancet 2009;374:210-221.
25. Jones G, Sebba A, Gu J, et al. Comparison of tocilizumab monotherapy versus methotrexate monotherapy in patients with moderate to severe rheumatoid arthritis: the AMBITION study. Ann Rheum Dis 2010;69:88-96.
26. Maini RN, Taylor PC, Szechinski J, et al. Double-blind randomized controlled clinical trial of the interleukin-6 receptor antagonist, tocilizumab, in European patients with rheumatoid arthritis who had an incomplete response to methotrexate. Arthritis Rheum 2006;54:2817-2829.
27. Nishimoto N, Miyasaka N, Yamamoto K, et al. Study of active controlled tocilizumab monotherapy for rheumatoid arthritis patients with an inadequate response to methotrexate (SATORI): significant reduction in disease activity and serum vascular endothelial growth factor by IL-6 receptor inhibition therapy. Mod Rheumatol 2009;19:12-19.
28. Smolen JS, Beaulieu A, Rubbert-Roth A, et al. Effect of interleukin-6 receptor inhibition with tocilizumab in patients with rheumatoid arthritis (OPTION study): a double-blind, placebo-controlled, randomised trial. Lancet 2008;371:987-997.
29. Nishimoto N, Hashimoto J, Miyasaka N, et al. Study of active controlled monotherapy used for rheumatoid arthritis, an IL-6 inhibitor (SAMURAI): evidence of clinical and radiographic benefit from an x ray reader-blinded randomised controlled trial of tocilizumab. Ann Rheum Dis 2007;66:1162-1167.
30. Genovese MC, McKay JD, Nasonov EL, et al. Interleukin-6 receptor inhibition with tocilizumab reduces disease activity in rheumatoid arthritis with inadequate response to disease-modifying antirheumatic drugs: the tocilizumab in combination with traditional disease-modifying antirheumatic drug therapy study. Arthritis Rheum 2008;58:2968-2980.
31. Emery P, Keystone E, Tony HP, et al. IL-6 receptor inhibition with tocilizumab improves treatment outcomes in patients with rheumatoid arthritis refractory to anti-tumour necrosis factor biologicals: results from a 24-week multicentre randomised placebo-controlled trial. Ann Rheum Dis 2008;67:1516-1523.